MOLECULAR BASIS OF PYRIMIDINE 5'-NUCLEOTIDASE (P5N) DEFICIENCY AND FUNCTIONAL ANALYSIS OF P5N

嘧啶 5-核苷酸酶 (P5N) 缺陷的分子基础及 P5N 的功能分析

基本信息

项目摘要

In this study, we screened 73 subjects with non-spherocytic hemolytic anemia of unknown pathogenesis, and diagnosed 5 of pyruvate kinase, 10 of glucose-6-phosphate dehydrogenase, 1 of adenylate kinase and 1 of pyrimidine 5'-nucleotidase (P5N-I) deficient cases.We identified five novel mutations in nine families with P5N-I deficiency : two missense mutations (425C, 721C), one splicing mutation (339C), one 1-bp insertion (251-insA-252) and one 9-bp deletion (del 192-200). All patients are homozygous for each mutation.We expressed mutant P5N-I with 425C and 721C in Cos-7 cells, and examined their intracellular stability. The L124P (425C) showed approximately 20% residual activity and immunoreactive protein of a wild-type control, suggesting that the L124P was an unstable variant. The G241R(721C) had been demonstrated as a kinetic variant with lower affinity for cytidine monophosphate. This mutant was as stable as a control in Cos-7 cells, being compatible with previous results. We could c … More onclude that Gly241 is important for the substrate binding. Haplotype analysis showed that the 721C, which had been identified in five unrelated families, was a founder mutation. Since proteasome inhibitors restored the stability of the L142P, the L142P increases the susceptibility to the degradation by ubiquitin-proteasome pathway.To examine physiological significance of P5N-I in non-erythroid cells, we established a line of transgenic mouse, which ubiquitously overexpressed human P5N-I. Transgene expression was detected in both liver and kidney. However, expression levels are within 2 times of normal controls. Effects of transgene-derived P5N-I on liver and kidney are being analyzed.The P5N-I gene can be induced by alpha-interferon, and the expression is augmented in lymphocytes of patients with HIV infection or autoimmune diseases such as SLE. From these observations, the P5N-I has been suggested to have any roles on immune response. We examined effects of the P5N-I on acute immunity of influenza infection ; however, overexpression of the P5N-I did not modify immune responses of infected cells. Further studies will require gaining insights on immunological roles of P5N-I. We thank Takako Hamada and Shin-ichi Okada for their excellent technical supports. Less
In this study, we screened 73 subjects with non-sphere-hemolytic anemia of unknown pathogenesis, and diagnosed 5 of pyruvate kinase, 10 of glucose-6-phosphate dehydrogenase, 1 of adenylate kinase and 1 of pyrimidine 5'-nucleotidase (P5N-I) deficient cases.We identified five novel mutations in nine families with P5N-I deficiency : two错义突变(425c,721c),一个剪接突变(339c),一个1 bp插入(251-INSA-252)和一个9 bp缺失(DEL 192-200)。所有患者在每个突变中都是纯合的。我们在COS-7细胞中用425C和721C表达突变体P5N-I,并检查了其细胞内稳定性。 L124p(425C)的残留活性约为20%,并具有野生型对照的免疫反应性蛋白质,这表明L124p是不稳定的变体。 G241R(721C)已被证明是一种对胞苷单磷酸的亲和力较低的动力学变体。该突变体与COS-7细胞中的对照一样稳定,与先前的结果兼容。我们可以……更多地说,Gly241对于底物结合很重要。单倍型分析表明,在五个无关家族中已鉴定出的721C是一个创始人突变。由于蛋白酶体抑制剂恢复了L142P的稳定性,因此L142P增加了泛素蛋白蛋白蛋白酶体途径降解的敏感性。要检查p5n-i在非雌激素细胞中的物理意义,我们在非毛细血管中的物理意义,我们建立了一种转基因小鼠的线,这些小鼠是ubiquicalliquicallicalliquicalliquicalliquicalliquicalliquicallicalliquicalliquicalliquicallicalliperapialed expercaced holduts p5n-i。在肝脏和肾脏中都检测到转基因表达。但是,表达水平在正常对照的2倍之内。转基因衍生的P5N-I对肝脏和肾脏的影响正在分析中。p5N-I基因可以由α-I-I-I-I-I-I基因诱导,并且在HIV感染或自身免疫性疾病的患者的淋巴细胞中增强了表达。从这些观察结果中,已经提出P5N-I在免疫响应中起任何作用。我们检查了P5N-I对影响力感染的急性免疫学的影响;但是,P5N-I的过表达不会改变感染细胞的免疫血液。进一步的研究将需要对P5N-I的免疫学作用有所了解。我们感谢Takako Hamada和Shin-ichi Okada的出色技术支持。较少的

项目成果

期刊论文数量(34)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kanno, H., Fujii, H., Miwa, S.: "Physiological significance and molecular genetics of red cell enzymes involved in the ribonucleotide metabolism"Proc. Japan Acad. 78(10). 287-292 (2002)
Kanno,H.,Fujii,H.,Miwa,S.:“参与核糖核苷酸代谢的红细胞酶的生理意义和分子遗传学”Proc。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Morimoto A, Ueda I, Hirashima Y, Sawai Y, Usuku T, Kano G, Kuriyama K, Todo S, Sugimoto T, Kanno H, Fujii H, Imashuku S: "A novel missense mutation (1060G→C) in the phosphoglycerate kinase gene in a Japanese boy with chronic hemolytic anemia, developmenta
Morimoto A、Ueda I、Hirashima Y、Sawai Y、Usuku T、Kano G、Kuriyama K、Todo S、Sugimoto T、Kanno H、Fujii H、Imashuku S:“磷酸甘油酸激酶中的一种新型错义突变 (1060G→C)患有慢性溶血性贫血的日本男孩的基因,正在发育
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Murakami K, Kanno H, Tancabelic J, Fujii H: "Gene expression and biological significance of hexokinase in erythroid cells."Acta Haematol. 108. 204-209 (2002)
Murakami K、Kanno H、Tancabelic J、Fujii H:“红系细胞中己糖激酶的基因表达和生物学意义。”Acta Haematol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Morimoto, A., Ueda, I., Kannno, H., Fujii, H., Imashuku S., et al.: "A novel missense mutation (1060G→C) in the phosphoglycerate kinase gene in a Japanese boy with chronic hemolytic anemia, developmental delay and rhabdomyolysis"Brit.J.Haematol. 122. 1009
Morimoto, A.、Ueda, I.、Kannno, H.、Fujii, H.、Imashuku S. 等人:“一名患有慢性溶血性贫血的日本男孩的磷酸甘油酸激酶基因中存在一种新的错义突变 (1060G→C)贫血、发育迟缓和横纹肌溶解症”Brit.J.Haematol. 122. 1009
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Aizawa S et al.: "Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency."Am J Hematol. 73. 68-72 (2003)
Aizawa S 等人:“丙酮酸激酶缺乏症患者的脾脏中红细胞生成无效。”Am J Hematol。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
共 13 条
  • 1
  • 2
  • 3
前往

FUJII Hisaichi的其他基金

Screening for causative genes in unknown hemolytic anemia
未知溶血性贫血致病基因的筛查
  • 批准号:
    17591013
    17591013
  • 财政年份:
    2005
  • 资助金额:
    $ 2.18万
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
    Grant-in-Aid for Scientific Research (C)
Molecular analysis of hereditary hemolytic anemia due to red cell enzyme anomalies
红细胞酶异常所致遗传性溶血性贫血的分子分析
  • 批准号:
    10670971
    10670971
  • 财政年份:
    1998
  • 资助金额:
    $ 2.18万
    $ 2.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

胞嘧啶脱氨酶APOBEC突变特征预测监控膀胱癌免疫治疗疗效的机制与应用研究
  • 批准号:
    82173076
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
能够在基因组中同时突变腺嘌呤和胞嘧啶的碱基编辑工具的研究
  • 批准号:
    31971366
  • 批准年份:
    2019
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
具有抗EGFR/PIK3CA双突变耐药的噻吩并(联)嘧啶类多靶点抑制剂的设计合成与抗NSCLC活性研究
  • 批准号:
    21967009
  • 批准年份:
    2019
  • 资助金额:
    40 万元
  • 项目类别:
    地区科学基金项目
癌细胞基因组中尿嘧啶修复引发突变的分子机制
  • 批准号:
    81872305
  • 批准年份:
    2018
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
利用靶向性胞嘧啶脱氨酶诱导抗体亲和力成熟
  • 批准号:
    31870927
  • 批准年份:
    2018
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Impact of ATR's role in translesion synthesis on prevention of DNA damage induced mutagenesis and chromosomal instability
ATR 在跨损伤合成中的作用对预防 DNA 损伤诱导的突变和染色体不稳定性的影响
  • 批准号:
    10634852
    10634852
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
    $ 2.18万
  • 项目类别:
Identifying recurrent driver mutations in skin cancers by targeted UV damage sequencing
通过靶向紫外线损伤测序识别皮肤癌中的复发性驱动突变
  • 批准号:
    10645759
    10645759
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
    $ 2.18万
  • 项目类别:
Applications of the long-term culture human primordial germ cell-like cells to toxicological assessments and mechanistic studies on chemically caused heritable human health threats
长期培养人类原始生殖细胞样细胞在化学引起的遗传性人类健康威胁的毒理学评估和机制研究中的应用
  • 批准号:
    10666200
    10666200
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
    $ 2.18万
  • 项目类别:
Elucidating the mechanism of Ga13 mediated tumor suppression in pancreatic cancer
阐明 Ga13 介导的胰腺癌肿瘤抑制机制
  • 批准号:
    10736355
    10736355
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
    $ 2.18万
  • 项目类别:
Mitochondrial translesion DNA synthesis
线粒体跨损伤 DNA 合成
  • 批准号:
    10587813
    10587813
  • 财政年份:
    2023
  • 资助金额:
    $ 2.18万
    $ 2.18万
  • 项目类别: